Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for bosutinib

  1. Bosutinib for previously treated chronic myeloid leukaemia (TA401)

    Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA401

  2. Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)

    NICE is unable to make a recommendation about the use in the NHS of bosutinib (Bosulif) for untreated chronic myeloid leukaemia in adults because no evidence submission was received from Pfizer. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    17 April 2019

    Sections for TA576

  3. Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

    Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA813

  4. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

    Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA451

  5. History of NICE

    First drug approved from old Cancer Drugs Fund In July we approved bosutinib (Bosulif, Pfizer) which treats some people with chronic...

  6. Bosutinib for previously treated chronic myeloid leukaemia (TA299)

    This guidance has been updated and replaced by NICE technology appraisal guidance 401. 

    Technology appraisal guidance
    Published
    27 November 2013